ArticleJournal of pediatric gastroenterology and nutrition2011
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease.
Article in Journal of pediatric gastroenterology and nutrition, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.JAMA pediatrics · 2015Pooled it
- Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study.Journal of clinical pharmacology · 2026Article
- Pharmacokinetics and Childhood Obesity: Pathophysiological Basis and Challenges in Choosing the Ideal Body Size Descriptor.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A serum-induced gene signature in hepatocytes is associated with pediatric nonalcoholic fatty liver disease.Journal of pediatric gastroenterology and nutrition · 2024Article
- Perioperative Acetaminophen Dosing in Obese Children.Children (Basel, Switzerland) · 2023Review
- Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review.Livers · 2023Article
- Acetaminophen pharmacokinetics in infants and children with congenital heart disease.Paediatric anaesthesia · 2023Article
- Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations.Frontiers in pharmacology · 2022Review
- Prescribing drugs to overweight and obese children: Balancing efficacy and safety.Paediatrics & child health · 2021Review
- Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.Clinical pharmacology and therapeutics · 2021Article
- Practical Challenges-Use of Paracetamol in Children and Youth Who are Overweight or Obese: A Narrative Review.Paediatric drugs · 2020Review
- Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children.Paediatric drugs · 2019Review
- Product Labeling of Drugs Commonly Administered to Children and Adults with Obesity.Pharmaceutical regulatory affairs : open access · 2019Article
- Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.Toxicological sciences : an official journal of the Society of Toxicology · 2018Article
- Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.Hepatology (Baltimore, Md.) · 2017Article
- Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.Clinical pharmacokinetics · 2016Observational
- Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression.Drug metabolism and disposition: the biological fate of chemicals · 2016Article
- Can paracetamol (acetaminophen) be administered to patients with liver impairment?British journal of clinical pharmacology · 2016Review
- Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.Drug metabolism and disposition: the biological fate of chemicals · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectives: The aim of the study was to evaluate UDP-glucuronyltransferase activity and the pharmacokinetics of a single oral dose of acetaminophen (APAP) in children with nonalcoholic fatty liver disease (NAFLD). PATIENTS AND
methods: Twelve boys 10 to 17 years old with biopsy-proven NAFLD and 12 age- and sex-matched controls without NAFLD were recruited. Following administration of a single oral dose of APAP (5 mg/kg, maximum 325 mg), APAP and its glucuronide metabolite (APAP-G) were measured in plasma, urine, and sputum at various intervals up to 24 hours. The activity of UDP-glucuronyltransferase was estimated by the plasma ratio of APAP-G to APAP at 4 hours.
results: Following administration of APAP, children with NAFLD had significantly higher concentrations of APAP-G in serum (P = 0.0071) and urine (P = 0.0210) compared with controls. No significant differences in APAP pharmacokinetics parameters were observed between the 2 groups.
conclusions: APAP glucuronidation is altered in children with fatty liver disease. Despite the altered disposition of this metabolite, the pharmacokinetics of a single 5 mg/kg dose of APAP is the same in children with NAFLD as in children with normal liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.